Bronchiectasisthe Airway Mycobiome Characterization

Overview

About this study

The purpose of this study is to describe the airway mycobiome in patients with bronchiectasis and to identify microbial signatures associated with eosinophilic inflammation, as well as disease severity and control.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients with bronchiectasis visiting the bronchiectasis clinic on Gonda 18S.

Exclusion Criteria:

Bronchiectasis due to Cystic Fibrosis.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/17/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Joseph Skalski, M.D.	Open for enrollment	Contact information: Amjad Kanj M.D., M.P.H. Kanj.Amjad@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joseph Skalski, M.D.

Open for enrollment

Contact information:

Amjad Kanj M.D., M.P.H.

Kanj.Amjad@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials